Condition: Pompe Disease · Sponsor: Shionogi
The purpose of this study is to evaluate the safety, pharmacodynamics (PD), and exploratory clinical efficacy of S-606001 in adult participants with LOPD as an add-on to ERT.
This description comes directly from the study's public registry record.
Shionogi Clinical Trials Administrator Clinical Support Help Line · 800-849-9707 · Shionogiclintrials-admin@shionogi.co.jp
Always discuss trial participation with your own doctor first.
| University of California - Irvine Medical Center | Irvine, California, United States | Recruiting |
| University of Florida (UF) - Gainesville | Gainesville, Florida, United States | Recruiting |
| Emory University Hospital | Atlanta, Georgia, United States | Recruiting |
| Washington University in St. Louis | St Louis, Missouri, United States | Recruiting |
| Duke University Medical Center | Durham, North Carolina, United States | Recruiting |
| Cincinnati Children's Hospital Medical Center | Cincinnati, Ohio, United States | Recruiting |
| University of Pennsylvania | Philadelphia, Pennsylvania, United States | Recruiting |
| University of Pittsburgh School of Medicine | Pittsburgh, Pennsylvania, United States | Recruiting |
| Lysosomal and Rare Disorders Research and Treatment Center (LDRTC) | Fairfax, Virginia, United States | Recruiting |
| UZ Leuven | Leuven, Belgium | Recruiting |
| Aarhus University Hospital | Aarhus, Denmark | Recruiting |
| HLC Hopital Pierre Wertheimer | Bron, France | Recruiting |
+ 16 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07123155